[The development of therapeutics targeting oxidative stress in prostate cancer]

Masaki Shiota, Akira Yokomizo, Seiji Naito

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Oxidative stress is caused by increased reactive-oxygen species (ROS) due to augmented ROS production and impaired anti-oxidative capacity. Recently, oxidative stress has been revealed to promote castration resistance via androgen receptor(AR)-dependent pathway such as AR overexpression, AR cofactor, and AR post-translational modification as well as AR-independent pathway, leading to the emergence of castration-resistant prostate cancer (CRPC). Therefore, antioxidants therapy using natural and chemical ROS scavengers and inhibitors of ROS production seems to be a promising therapy for CRPC as well as preventing castration resistance. However, at present, the application to therapeutics is limited. Therefore, further research on oxidative stress in prostate cancer, as well as on the development for clinical application would be needed.

Original languageEnglish
Pages (from-to)2131-2135
Number of pages5
JournalNihon rinsho. Japanese journal of clinical medicine
Volume72
Issue number12
Publication statusPublished - Dec 1 2014

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of '[The development of therapeutics targeting oxidative stress in prostate cancer]'. Together they form a unique fingerprint.

Cite this